Francisella tularensis is a gram-negative coccobacillus that causes a condition commonly referred to as tularemia. There has been a dramatic increase in tularemia cases reported in South Dakota, many of which were challenging to diagnose due to atypical clinical manifestations. We describe an interesting case of pneumonic tularemia and summarize six similar cases, several of which presented with lung nodules suggestive of malignancy. According to the literature, this is only the third outbreak of pneumonic tularemia reported in the U.S. We believe it is important for clinicians to be aware of the increased incidence of tularemia in the area and to be vigilant in the diagnosis and management of these atypically presenting cases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Current vaccine strategies and novel approaches to combatting Francisella infection.
Vaccine
April 2024
Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA. Electronic address:
Article Synopsis
- * There are currently no approved vaccines for Tularemia in the U.S., and existing traditional vaccination methods have safety and effectiveness issues.
- * The text highlights the need for innovative vaccine strategies and discusses current challenges in vaccine development against F. tularensis to enhance protection.
An Unusual Etiology of Fluorodeoxyglucose Avid Intrathoracic Lymph Nodes.
Prague Med Rep
February 2024
Department of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, USA.
A middle-aged man in his 50s, active smoker, presented to the pulmonary office for lung cancer evaluation. On a low-dose computed tomography for lung cancer screening, he was found to have an 8 mm endobronchial lesion in the right main stem bronchus. A PET-CT revealed no endobronchial lesion, but incidentally, fluorodeoxyglucose (FDG) avidity was present in the right hilar (SUV 13.
View Article and Find Full Text PDFTularemia treatment: experimental and clinical data.
Front Microbiol
January 2024
Centre National de Référence Francisella tularensis, CHU Grenoble Alpes, Grenoble, France.
Tularemia is a zoonosis caused by the Gram negative, facultative intracellular bacterium . This disease has multiple clinical presentations according to the route of infection, the virulence of the infecting bacterial strain, and the underlying medical condition of infected persons. Systemic infections (e.
View Article and Find Full Text PDFEfficacy of Doxycycline and Ciprofloxacin for Treatment of Pneumonic Tularemia in Cynomolgus Macaques.
Clin Infect Dis
January 2024
Office of Biodefense Research Resources and Translational Research, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Background: The incidence of pneumonic tularemia is very low; therefore, it is not feasible to conduct clinical efficacy testing of tularemia medical countermeasures (MCMs) in humans. The US Food and Drug Administration's Animal Model Qualification Program under the Drug Development Tools Program is a regulatory pathway for animal models used in MCM efficacy testing and approval under the Animal Rule. The National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority worked together to qualify the cynomolgus macaque model of pneumonic tularemia.
View Article and Find Full Text PDFSystematic Review: Clinical Features, Antimicrobial Treatment, and Outcomes of Human Tularemia, 1993-2023.
Clin Infect Dis
January 2024
Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.
Article Synopsis
- Francisella tularensis is a highly infectious bacterium that causes tularemia and poses a potential bioterrorism risk, with just 10 organisms needed to cause disease.
- A systematic review of 8878 publications found 410 articles detailing 870 cases treated with various antibiotics, mostly from the U.S., Turkey, and Spain, primarily presenting as ulceroglandular and pneumonic forms.
- The study concluded that aminoglycosides, fluoroquinolones, and tetracyclines are generally effective, with ciprofloxacin showing particularly good outcomes for patients with pneumonic disease, resulting in no fatalities and fewer complications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!